Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
RNA interference (RNAi) is a universal and evolutionarily conserved phenomenon of post-transcriptional gene silencing by means of sequence-specific mRNA degradation, triggered by small double-stranded RNAs. Because this mechanism can be efficiently induced in vivo by expressing target-complementary short hairpin RNA (shRNA) from non-viral and viral vectors, RNAi is attractive for functional genomics and human therapeutics. Here we systematically investigate the long-term effects of sustained high-level shRNA expression in livers of adult mice. Robust shRNA expression in all the hepatocytes after intravenous infusion was achieved with an optimized shRNA delivery vector based on duplex-DNA-containing adeno-associated virus type 8 (AAV8). An evaluation of 49 distinct AAV/shRNA vectors, unique in length and sequence and directed against six targets, showed that 36 resulted in dose-dependent liver injury, with 23 ultimately causing death. Morbidity was associated with the downregulation of liver-derived microRNAs (miRNAs), indicating possible competition of the latter with shRNAs for limiting cellular factors required for the processing of various small RNAs. In vitro and in vivo shRNA transfection studies implied that one such factor, shared by the shRNA/miRNA pathways and readily saturated, is the nuclear karyopherin exportin-5. Our findings have fundamental consequences for future RNAi-based strategies in animals and humans, because controlling intracellular shRNA expression le…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cellular toxicity can, for example, be observed in rAAV shRNA overexpression studies in which ubiquitous promoters were used that caused saturation of cellular miRNA pathways [88].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“However, the relatively large size, the requirement that the transcript starts with a G or A, the sometimes too active transcription, and the sensitivity to specific cellular profiles make the human U6 promoter a less versatile promoter [88,131,132].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“Consistent with this possibility, when multiple miRNAs are packaged within a single construct, they may compete for processing by the cellular miRNA biogenesis machinery, leading to reduced efficiency in individual miRNA maturation and function 44,45 .”
From rAAV-mediated Multi-miRNA Delivery Targeting MAPK Pathway Suppresses Laser-induced Choroidal Neovascularization in Mice (2026) · cites this paper as [44]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Identification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355
Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs
Yi, R., Qin, Y., Macara, I. G., & Cullen, B. R. (2003) · Genes & Development · doi:10.1101/gad.1158803 · Cited by 3,010
Nuclear Export of MicroRNA Precursors
Lund, E., Güttinger, S., Calado, A., Dahlberg, J. E., & Kutay, U. (2004) · Science · doi:10.1126/science.1090599 · Cited by 2,714
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., & Sarnow, P. (2005) · Science · doi:10.1126/science.1113329 · Cited by 2,521
Self-citationExportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs
BOHNSACK, M. T., CZAPLINSKI, K., & GÖRLICH, D. (2004) · RNA · doi:10.1261/rna.5167604 · Cited by 1,433
Cited by
Items 801–900 of 1,001
Adams, F. F., Heckl, D., Hoffmann, T., Talbot, S. R., Kloos, A., Thol, F. R., Heuser, M., Zuber, J. A., Schambach, A., & Schwarzer, A. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.05.032 · Cited by 25
“3 knockdown in a number of instances, ineffective and imprecise processing caused accumulation of unprocessed transcripts resulting in severe off-target effects due to obstruction of the endogenous miRNA pathway [4].”
BackgroundSpada, M., Pugliesi, C., Fambrini, M., Palpacelli, D., Caneo, A., & Pecchia, S. (2025) · Agronomy · doi:10.3390/agronomy15010194 · Cited by 24
Polycation-based nanoparticles for RNAi-mediated cancer treatment
Ballarín-González, B., Ebbesen, M. F., & Howard, K. A. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.09.023 · Cited by 26
Antisense-Mediated RNA Targeting: Versatile and Expedient Genetic Manipulation in the Brain
Zalachoras, I., Evers, M. M., van Roon-Mom, W. M. C., Aartsma-Rus, A. M., & Meijer, O. C. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00010 · Cited by 24
“The 20-mer AONs with 2′-methoxy-ethyl modification and a phosphorothioate backbone were designed to target a sequence just 3′ of the translation start site of the murine α-4 integrin mRNA to block its translation (Figure 1B).”
BackgroundMethodInfluentialLinck-Paulus, L., Hellerbrand, C., Bosserhoff, A., & Dietrich, P. (2020) · Cells · doi:10.3390/cells9010114 · Cited by 34
“Moreover, another critical concern is that induction of miRNAs via non-viral and viral vectors leads to liver toxicity and death in mice due to oversaturation of cellular miRNA pathways [332].”
BackgroundThe potential therapeutic applications of long non-coding RNAs
Tamblin-Hopper, P., Kiss‐Toth, E., Sudbery, I. M., Young, D., & Wilkinson, J. M. (2024) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2024.12 · Cited by 25
Implication of miRNA in the diagnosis and treatment of breast cancer
Castañeda, C. A., Agulló-Ortuño, M. T., Vara, J. Á. F., Cortés-Funes, H., Gómez, H., & Ciruelos, E. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.40 · Cited by 25
Efficient inhibition of HIV-1 replication by an artificial polycistronic miRNA construct
Zhang, T., Cheng, T., Wei, L., Cai, Y., Yeo, A. E. T., Han, J., Yuan, Y. A., Zhang, J., & Xia, N. (2012) · Virology Journal · doi:10.1186/1743-422x-9-118 · Cited by 24
“However, the high expression level of RNA polymerase III promoters that are used to transcribe shRNAs and lhRNAs may increase toxicity due to saturation of the RNAi machinery [33,40].”
BackgroundWu, J. X., Liu, S., Yu, J., Zhou, G., Rao, D., Jay, C. M., Kumar, P., Sanchez, R., Templeton, N. S., Senzer, N. N., et al. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2013.84 · Cited by 24
Matskevich, A. A., Jung-Shiu, J., Schümann, M., Cascalló, M., & Moelling, K. (2009) · Journal of Innate Immunity · doi:10.1159/000191408 · Cited by 24
“The enhanced response of the immune system to viral vectors makes it difficult for repetitive gene therapy in patients. Grimm et al. [”
BackgroundGene-Targeted Therapies for the Central Nervous System
Miller, T. M., Smith, R. A., Kordasiewicz, H. B., & Kaspar, B. K. (2008) · Archives of Neurology · doi:10.1001/archneur.65.4.nnr70007 · Cited by 24
Modulation of Cellular Invasion by VEGF-C Expression in Squamous Cell Carcinoma of the Head and Neck
Bock, J. M., Sinclair, L. L., Bedford, N. S., Jackson, R. E., Lee, J. H., & Trask, D. K. (2008) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.134.4.355 · Cited by 27
“Current studies with adeno-associated virus have also shown efficacy but are complicated by significant toxic effects due to saturation of intracellular RNAi protein and enzymatic resources.(35) Clinical cancer therapies to inhibit oncogene expression through the delivery of RNAi are evolving from a vague benchtop con…”
BackgroundStudies of Efficacy and Liver Toxicity Related to Adeno-Associated Virus–Mediated RNA Interference
Sun, C., Wu, T., Chen, C., Wu, P., Shih, Y., Tsuneyama, K., & Tao, M. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.239 · Cited by 26
“However, in other reports, similar shRNA-encoding AAV8 vectors targeting HBV and a variety of other genes caused dose-dependent acute hepatitis and lethality in the majority of treated mice (Grimm et al., 2006, 2010).”
BackgroundMethodResultInfluentialA direct comparison of strategies for combinatorial RNA interference
Lambeth, L. S., Hateren, N. J. V., Wilson, S. A., & Nair, V. (2010) · BMC Molecular Biology · doi:10.1186/1471-2199-11-77 · Cited by 24
“One concern over the use of multiple promoters for co-RNAi, and indeed strong promoters such as U6 in general, is the saturation of the RNAi machinery resulting in impaired processing of endogenous miRNAs [22,45,46].”
BackgroundExploiting microRNAs As Cancer Therapeutics
Robb, T. J., Reid, G., & Blenkiron, C. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0476-7 · Cited by 25
Askou, A. L., Benckendorff, J. N. E., Holmgaard, A., Storm, T., Aagaard, L., Bek, T., Mikkelsen, J. G., & Corydon, T. J. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.079 · Cited by 24
“36 40 As reviewed by Grimm, 41 evidence from the literature strongly suggests that impeding with endogenous miRNA activity by saturating Exportin-5 and Argonaute proteins constitute the major risks.”
Self-citationRNA Interference inhibits Hepatitis B Virus of different genotypes in Vitro and in Vivo
Zhang, Y., Cheng, T., Cai, Y., Yuan, Q., Liu, C., Zhang, T., Xia, D., Li, R.-Y., Yang, L., Wang, Y.-B., et al. (2010) · BMC Microbiology · doi:10.1186/1471-2180-10-214 · Cited by 24
“However, a previous study noted that U6 Pol III-expressed shRNAs may cause serious toxicity in vivo by saturating the endogenous miR pathway [25].”
BackgroundRead, M. L., Mir, S., Spice, R., Seabright, R. J., Suggate, E. L., Ahmed, Z., Berry, M., & Logan, A. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1321 · Cited by 24
“In particular, toxicity can result from saturation of the endogenous RNAi export machinery [11], induction of innate immune responses [12–14] and off-target silencing of unintended mRNAs [15,16].”
BackgroundHirai, T., Enomoto, M., Machida, A., Yamamoto, M., Kuwahara, H., Tajiri, M., Hirai, Y., Sotome, S., Mizusawa, H., Shinomiya, K., et al. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.035 · Cited by 27
“Because both RNA forms share intracellular machinery for their expression in mammalian cells, we sought to clarify whether overexpression of shRNA decreased the processing of endogenous miRNA (Grimm et al., 2006; Rossi, 2008).”
Qiu, L., Rivera‐Pérez, J. A., & Xu, Z. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018778 · Cited by 24
“It has been shown that high levels of siRNA or shRNA expression can cause toxicity in mice [24,25].”
Rhee, S. W., Stimers, J. R., Wang, W., & Pang, L. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.148866 · Cited by 24
“Grimm et al. (2006) reported that the adeno-associated virus-mediated sustained high levels of siRNA expression (driven by U6 or H1 promoter) oversaturated the in vivo miRNA pathway and caused deadly liver damage, whereas expression of the siRNA from a liver-specific pol II promoter was safe and…”
BackgroundRNAi Therapy for Neurodegenerative Diseases
Boudreau, R. L., & Davidson, B. L. (2006) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)75003-7 · Cited by 28
RNA Interference as Potential Therapy — Not So Fast
Marsden, P. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmcibr063864 · Cited by 24
Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery
Teng, X.-Q., Qu, J., Li, G., Zhuang, H.-H., & Qu, Q. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.824299 · Cited by 24
“Additionally, exogenous siRNA may compete with endogenous RNA, resulting in oversaturation (Grimm et al., 2006).”
BackgroundThe future of sickle cell disease therapeutics rests in genomics
Wonkam, A. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.049765 · Cited by 23
“For example, studies in mice showed that miRNA therapy can be toxic, showing dose-dependent liver injury, ultimately, causing death in numerous experiments (Grimm et al., 2006).”
Luo, T., Jiang, M., Cheng, Z., Lin, Y., Chen, Y., Zhang, Z., Zhou, J., Zhou, W., Yu, X., Li, S., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01961-9 · Cited by 23
Jafari, N., Peeridogaheh, H., Bohlooli, S., Oyong, G. G., Shirzad, Z., Alibeiki, F., Asl, S. H., & Zargar, S. J. (2013) · Europe PMC (PubMed Central) · Cited by 30
Potential Use of Polyamidoamine Dendrimer Conjugates with Cyclodextrins as Novel Carriers for siRNA
Arima, H., Motoyama, K., & Higashi, T. (2011) · Pharmaceuticals · doi:10.3390/ph5010061 · Cited by 25
“, liver toxicity in mice receiving high doses of short hairpin RNA (shRNA) [5,6].”
BackgroundMaczuga, P., Koornneef, A., Borel, F., Petry, H., van Deventer, S. J. H., Ritsema, T., & Konstantinova, P. S. (2012) · BMC Biotechnology · doi:10.1186/1472-6750-12-42 · Cited by 28
“There are cases reporting severe toxicity after administration of high doses of vectors encoding shRNA [9,10].”
BackgroundMathew, S. F., Crowe‐McAuliffe, C., Graves, R. S., Cardno, T. S., McKinney, C., Poole, E. S., & Tate, W. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122176 · Cited by 25
“Expressed shRNAs can compete with existing cellular small RNAs for the RNAi processing machinery [59].”
BackgroundLi, L., Haider, H. K., Wang, L., Lü, G., & Ashraf, M. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00339.2011 · Cited by 23
Identification of Allele-Specific RNAi Effectors Targeting Genetic Forms of Parkinson's Disease
Sibley, C. R., & Wood, M. J. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026194 · Cited by 23
“Reports have been published of shRNAs leading to significant toxicity in vivo which can have fatal consequences in some animal models [19,20].”
Antiviral RNAi: Translating Science Towards Therapeutic Success
Shah, P. S., & Schaffer, D. V. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0549-8 · Cited by 23
“For example, it was shown in vivo that high levels of exogenous siRNAs can competitively interfere with the endogenous activity of miRNAs and the natural function of the RNAi pathway (113).”
BackgroundAttacking HIV-1 RNA versus DNA by sequence-specific approaches: RNAi versus CRISPR-Cas
Herrera-Carrillo, E., & Berkhout, B. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160060 · Cited by 25
Günther, A., Luczak, V., Abel, T. G., & Baumann, A. (2017) · Journal of Experimental Biology · doi:10.1242/jeb.154583 · Cited by 24
“Cytotoxic effects of shRNAs have previously been shown to be caused by overloading of the endogenous miRNA machinery (Börner et al., 2013; Grimm et al., 2006, 2010; McBride et al., 2008; Yi et al., 2005).”
BackgroundSnyder, L. L., Ahmed, I., & Steel, L. F. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp657 · Cited by 30
“For instance, AAV vectors directing the expression of certain shRNAs in the liver were lethal to mice when delivered at high dose ( 20 ).”
BackgroundRapid and Stable Knockdown of an Endogenous Gene in Retinal Pigment Epithelium
Paskowitz, D. M., Greenberg, K. P., Yasumura, D., Grimm, D., Yang, H., Duncan, J. L., Kay, M. A., LaVail, M. M., Flannery, J. G., & Vollrath, D. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.065 · Cited by 24
“In some cells that expressed the target construct at low levels, DsRed expression was more difficult to observe (Fig.”
Self-citationShan, Z., Lin, Q. X., Yang, M., Deng, C., Kuang, S., Zhou, Z., Xiao, D., Liu, X. Y., Lin, S., & Yu, X. (2008) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-9966-3 · Cited by 23
Accelerating Cancer Modeling with RNAi and Nongermline Genetically Engineered Mouse Models
Livshits, G., & Lowe, S. W. (2013) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top069856 · Cited by 23
“This is not ideal, as high shRNA expression has been associated with toxicity due to saturation of the endogenous miRNA machinery (Grimm et al. 2006).”
BackgroundCurrent State of Therapeutics for HTLV-1
Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L. (2024) · Viruses · doi:10.3390/v16101616 · Cited by 22
“The first anti-HIV-1, siPromA, was first identified in 2005 [309], and targeted the unique and highly conserved NK-κ B transcription factor sites in the HIV-1 promoter to induce potent epigenetic silencing [70,310–312].”
BackgroundZhu, Z., Shen, J., Ho, P. C., Hu, Y., Ma, Z., & Wang, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1563198 · Cited by 34
“In addition, off-target binding (Kamola et al., 2015), sequence-induced toxicity, and oversaturation of the endogenous RNA processing pathway affect the effectiveness of RNA-based approaches (Grimm et al., 2006).”
Hutson, T. H., Foster, E., Dawes, J. M., Hindges, R., Yáñez‐Muñoz, R. J., & Moon, L. D. F. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2626 · Cited by 24
“tent with previous studies showing that shRNA expression by Pol III promoters can result in cytotoxicity in vitro and fatality in vivo [40,44–47,49,71,72].”
Wang, X., Skelley, L. A., Wang, B., Mejia, A., Sapozhnikov, V., & Sun, Z. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.078 · Cited by 22
“It was reported that high doses of shRNAs, particularly the 25-mer shRNAs, caused toxicity and morbidity in animals within 1 month (Grimm et al., 2006).”
BackgroundProspects of RNAi and microRNA-based therapies for hepatitis C
Pan, Q., Tilanus, H. W., Janssen, H. L. A., & van der Laan, L. J. W. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902989970 · Cited by 22
“Polymerase III promoters, in particular U6, often excessively expresses shRNA, which has been shown to induce acute cytotoxicity [100].”
BackgroundTissue-Specific shRNA Delivery: A Novel Approach for Gene Therapy in Cancer
Ghatak, S., Hascall, V. C., Berger, F. G., Penas, M. M. O., Davis, C., Jabari, E., He, X., Norris, J. S., Dang, Y., Markwald, R. R., et al. (2008) · Connective Tissue Research · doi:10.1080/03008200802147845 · Cited by 22
“However, it may overload the nuclear export system and cause toxicity in vivo [6].”
BackgroundSelf-citationThe New Genetics and Natural versus Artificial Genetic Modification
Ho, M. (2013) · Entropy · doi:10.3390/e15114748 · Cited by 27
“A worst case scenario of toxic dsRNA came from a gene “therapy” experiment in mice reported in 2006, which killed more than 150 animals [150,151].”
BackgroundsiRNA Delivery for the treatment of ovarian cancer
Goldberg, M. S. (2013) · Methods · doi:10.1016/j.ymeth.2013.01.007 · Cited by 23
Größl, T., Hammer, E., Bien-Möller, S., Geisler, A., Pinkert, S., Röger, C., Poller, W., Kurreck, J., Völker, U., Vetter, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092188 · Cited by 19
“expression [14,26] and thus high vector doses used here, leading to”
BackgroundPoly(aminoether)–Gold Nanorod Assemblies for shRNA Plasmid-Induced Gene Silencing
Ramos, J., & Rege, K. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400080f · Cited by 22
Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9
Kieckhaefer, J. E., Maina, F., Wells, R. G., & Wangensteen, K. J. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1678725 · Cited by 23
Cheng, T., Teng, C., Tsai, W. H., Yeh, C., Wu, M. P., Hsu, H.-C., Hung, C., & Chang, W. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2008.102 · Cited by 22
New therapeutic targets for amyotrophic lateral sclerosis
Kuźma‐Kozakiewicz, M., & Kwieciński, H. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.542152 · Cited by 26
“The effect was probably due to saturation of the endogenous RNAi machinery [77].”
BackgroundShort interfering RNA-mediated gene silencing; towards successful application in human patients
Siomi, M. C. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.008 · Cited by 24
Therapeutic Potential of RNA Interference in Drug-Resistant Cancers
Lage, H. (2009) · Future Oncology · doi:10.2217/14796694.5.2.169 · Cited by 23
“Unfortunately, the investigation of the longterm effects of sustained high-level shRNA expression in mouse livers revealed material problems [77].”
BackgroundResultFactors Affecting EWS-FLI1 Activity in Ewing's Sarcoma
Herrero‐Martín, D., Fourtouna, A., Niedan, S., Riedmann, L. T., Schwentner, R., & Aryee, D. N. T. (2011) · Sarcoma · doi:10.1155/2011/352580 · Cited by 26
“Although some siRNA coupled to nanoparticles have proved to be useful in preclinical models either alone [129–132] or combined with other therapeutic agents as rapamycin [133], the general lack of clinical translation of some of these macromolecule-based strategies lies in the challenge of pharmacological delivery [13…”
BackgroundA review of antisense therapeutic interventions for molecular biological targets in asthma.
Popescu, F., & Popescu, F. (2007) · PubMed Central · Cited by 27
Transcriptional targeting of small interfering RNAs into cancer cells
Huynh, T. T., Wälchli, S., & Sioud, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.09.127 · Cited by 22
RNA surveillance—An emerging role for RNA regulatory networks in aging
Montano, M. A., & Long, K. K. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.02.002 · Cited by 22
The microRNA Let-7 and its exosomal form: Epigenetic regulators of gynecological cancers
Wang, F., Zhou, C., Zhu, Y., & Keshavarzi, M. (2024) · Cell Biology and Toxicology · doi:10.1007/s10565-024-09884-3 · Cited by 24
“Grimm et al. (Grimm et al. 2006) reported the administration of recombinant pre-mirnas using adeno-associated virus resulted in fatalities in mice due to extreme liver toxicity.”
BackgroundOncogene dependency and the potential of targeted RNAi-based anti-cancer therapy
Yan, R., Hallam, A., Stockley, P. G., & Boyes, J. (2014) · Biochemical Journal · doi:10.1042/bj20140173 · Cited by 23
Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene Therapy
Wozniak, J., Wandtke, T., Kopinski, P., & Chorostowska‐Wynimko, J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.044 · Cited by 21
“proposed the use of microRNAs, which have proven effective in posttranscriptional silencing of defective genes.(85,86) The retroviral vector encoding ribozyme specific for Z-AAT, and modified M-AAT mRNA not susceptible to its activity, allowed for simultaneous inhibition of Z-AAT expression and an increase in function…”
BackgroundProgress in the use of RNA interference as a therapy for chronic hepatitis B virus infection
Weinberg, M. S., & Arbuthnot, P. B. (2010) · Genome Medicine · doi:10.1186/gm149 · Cited by 24
Functional inhibition of chemokine receptor CCR2 by dicer-substrate-siRNA prevents pain development
Bégin-Lavallée, V., Midavaine, É., Dansereau, M., Tétreault, P., Longpré, J., Jacobi, A. M., Rose, S. D., Behlke, M. A., Beaudet, N., & Sarret, P. (2016) · Molecular Pain · doi:10.1177/1744806916653969 · Cited by 21
Roles of Nicotinamide N‐Methyltransferase in Obesity and Type 2 Diabetes
Liu, J.-R., Deng, Z.-H., Zhu, X., Zeng, Y.-R., Guan, X.-X., & Li, J.-H. (2021) · BioMed Research International · doi:10.1155/2021/9924314 · Cited by 24
Inhibition of Hepatitis E virus replication using short hairpin RNA (shRNA)
Kumar, A., Panda, S. K., Durgapal, H., Acharya, S. K., Rehman, S., & Kar, U. K. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2010.01.005 · Cited by 21
RNA Interference Inhibitors of Hepatitis B Virus
McCaffrey, A. P. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04974.x · Cited by 21
Stein, E. A., Pinkert, S., Becher, P. M., Geisler, A., Zeichhardt, H., Klopfleisch, R., Poller, W. C., Tschöpe, C., Laßner, D., Fechner, H., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu504 · Cited by 21
“Even though some groups reported cytotoxicity when expressing high amounts of shRNAs from AAV vectors [24], no such”
BackgroundTherapeutic Potential of RNA Interference in Pain Medicine
Tan, P.-H., Yang, L., & Ji, R. (2009) · The Open Nanomedicine Journal · doi:10.2174/1876386300902010057 · Cited by 24
“There has been a report demonstrating the death of mice after Pol III promoter-driven expression of shRNAs in the liver [46], in part due to saturation of the transport factor, exportin 5 that ferries miRNAs from the nucleus to the cytoplasm.”
Lin, Q., Ponnusamy, R., Widagdo, J., Choi, J. A., Ge, W., Probst, C., Buckley, T. J., Lou, M., Bredy, T. W., Fanselow, M. S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706069114 · Cited by 22
“In addition, we are fully aware of the potential off-target issue associated with the shRNA knockdown approach (32).”
BackgroundModarres, M., Shariati, L., Hejazi, Z., Shahbazi, M., Tabatabaiefar, M. A., & Khanahmad, H. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26412 · Cited by 24
Selected Strategies for the Delivery of siRNA In Vitro and In Vivo
Laufer, S. D., Detzer, A., Sczakiel, G., & Restle, T. (2010) · RNA technologies · doi:10.1007/978-3-642-12168-5_2 · Cited by 25
“However, evidently they can interfere with the endogenous microRNA pathway, thus causing severe side effects (Grimm et al. 2006; Snøve and Rossi 2006).”
BackgroundZhang, C., Freistaedter, A., Schmelas, C., Gunkel, M., Thi, V. L. D., & Grimm, D. (2021) · Hepatology Communications · doi:10.1002/hep4.1842 · Cited by 20
Self-citationDual-function AAV gene therapy reverses late-stage Canavan disease pathology in mice
Fröhlich, D., Kalotay, E., von Jonquières, G., Bongers, A., Lee, B., Suchowerska, A. K., Housley, G. D., & Klugmann, M. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1061257 · Cited by 21
“shRNA delivery (Grimm et al., 2006), we compromised on Nat8l silencing efficacy and opted for a miRNA design, resulting in a lower, 20–30% knockdown (Figure 2A).”
BackgroundWhen Cellular Networks Run Out of Control
Mockenhaupt, S., Schürmann, N., & Grimm, D. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-415795-8.00006-4 · Cited by 25
Self-citationIn vivo RNAi screens: concepts and applications
Crotty, S., & Pipkin, M. E. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.03.007 · Cited by 20
“Furthermore, strong expression of these basic shRNA stem loops has been associated with dose dependent toxicities, resulting from saturation of the endogenous RNAi machinery and displacement of endogenous microRNAs [20].”
BackgroundMechanism of Repeat-Associated MicroRNAs in Fragile X Syndrome
Kelley, K. M. M., Chang, S.-J. E., & Lin, S.-L. (2012) · Neural Plasticity · doi:10.1155/2012/104796 · Cited by 21
“Third, excessive RNA accumulation and cytotoxicity can be prevented by the NMD mechanism of a cellular intronic expression system, but not a direct expression system [46, 48].”
BackgroundMas, A., Spengler, R. M., Dufour, B. D., Wilson, M. S., Oakley, C. K., Sowada, M. J., McBride, J. L., & Davidson, B. L. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku979 · Cited by 22
“Early studies demonstrated in vivo RNAi-mediated toxicity due to saturation of the Exportin 5 pathway and buildup of shRNA sequences when expressed in the context of shRNA shuttles (37,38).”
Shih, Y., Sun, C., Chou, H.-H., Wu, T., Chen, C., Wu, P., Chen, Y.-C. E., Bissig, K., & Tao, M. (2015) · Scientific Reports · doi:10.1038/srep15259 · Cited by 21
Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing
Cambon, K., Zimmer, V., Martineau, S., Gaillard, M., Jarrige, M., Bugi, A., Miniarikova, J., Rey, M. J., Hässig, R., Dufour, N., et al. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.05.001 · Cited by 21
The state of gene therapy research in Africa, its significance and implications for the future
Arbuthnot, P. B., Maepa, M. B., Ely, A., & Pepper, M. S. (2017) · Gene Therapy · doi:10.1038/gt.2017.57 · Cited by 21
“[36] [37] [38] Gene therapy for HBV infection.”
BackgroundStrategies for improving the specificity of siRNAs for enhanced therapeutic potential
Gatta, A. K., Hariharapura, R. C., Udupa, N., Reddy, M. S., & Josyula, V. R. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1480607 · Cited by 21
“Saturation of RNAi machinery Concentration-dependent Saturation of RNAi machinery is an inevitable process, but it can be greatly reduced if used at lower concentrations (≤20 nM) [57,62]”
BackgroundThe therapeutic potential of RNA regulation in neurological disorders
Roovers, J., Jonghe, P. D., & Weckhuysen, S. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1542429 · Cited by 21
“Using promotors with only limited expression capacity, or co-expressing XPO5 has been shown to reduce these toxic effects [40,42].”
BackgroundAre We Studying Non-Coding RNAs Correctly? Lessons from nc886
Lee, Y. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084251 · Cited by 20
“The adverse effects of an siRNA (off-target activity and saturation of the miRNA machinery) are obvious [38,72].”
BackgroundGene knockdown in malaria parasites via non-canonical RNAi
Hentzschel, F., Mitesser, V., Fraschka, S. A. K., Krzikalla, D., Herrera-Carrillo, E., Berkhout, B., Bártfai, R., Mueller, A., & Grimm, D. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz927 · Cited by 20
“To express the GFP from PbGFPcon in cell culture, the gfp coding region was amplified from genomic DNA using primers P1/P2 and cloned into a self-complementary AAV vector plasmid via XhoI/NheI under the Cytomegalovirus (CMV) promoter (9).”
MethodSelf-citationRobust Hepatic Gene Silencing for Functional Studies Using Helper-Dependent Adenoviral Vectors
Ruiz, R., Witting, S. R., Saxena, R., & Morral, N. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.081 · Cited by 22
“In addition, adeno-associated virus (AAV)-mediated expression of shRNA has resulted in the death of animals at high doses of vector (Grimm et al. , 2006), which did not occur with our system.”
Bifunctional Short Hairpin RNA (bi-shRNA): Design and Pathway to Clinical Application
Rao, D. D., Senzer, N. N., Wang, Z., Kumar, P., Jay, C. M., & Nemunaitis, J. J. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-119-6_14 · Cited by 19
Proteome-wide systems genetics identifies UFMylation as a regulator of skeletal muscle function
Molendijk, J., Blazev, R., Mills, R. J., Ng, Y., Watt, K. I., Chau, D., Gregorevic, P., Crouch, P. J., Hilton, J. B. W., Lisowski, L., et al. (2022) · eLife · doi:10.7554/elife.82951 · Cited by 20
Advances in Recombinant Adeno-Associated Virus Vectors for Neurodegenerative Diseases
Li, L., Vasan, L., Kartono, B., Clifford, K. P., Attarpour, A., Sharma, R., Mandrozos, M., Kim, A., Zhao, W., Belotserkovsky, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11102725 · Cited by 20
“…overcome with AAV-delivered gene silencing of short-hairpin RNAs (shRNAs) [115], the latter is not trivial either due to the observation that the supraphysiological expression of shRNA silencing precursors can cause toxicity by competing with the processing and function of endogenous miRNAs [116].”
BackgroundYoon, A. R., Lee, S.-Y., Kim, J. H., Park, Y., Koo, T., & Yun, C. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.017 · Cited by 19
“17,18 Collectively, these fi ndings suggest that employing Ad/ABE- TP53-EGFR for multi-editing of oncoSNPs could sensitize ge fi tinib-resis-tant cancer cells in a mutation-speci fi c manner related to TP53 and/or EGFR , but their unexpected effects in cancers with wild-type genes warrant more…”
Machitani, M., Sakurai, F., Katayama, K., Tachibana, M., Suzuki, T., Matsui, H., Yamaguchi, T., & Mizuguchi, H. (2013) · Virus Research · doi:10.1016/j.virusres.2013.09.021 · Cited by 19
Competition potency of siRNA is specified by the 5′-half sequence of the guide strand
Yoo, J. W., Kim, S., & Lee, D.-K. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.12.099 · Cited by 19
Systemic Delivery and Quantification of Unformulated Interfering RNAs In Vivo
Morin, A., Gallou‐Kabani, C., Mathieu, J. R. R., & Cabon, F. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789630820 · Cited by 20
Knockdown of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's disease
Horvath, L., van Marion, I., Taï, K., Nielsen, T. T., & Lundberg, C. (2011) · The Journal of Gene Medicine · doi:10.1002/jgm.1555 · Cited by 21
“shRNAs in vivo [19,30] and different approaches to overcome this have been developed [31].”
BackgroundSequence-non-specific effects generated by various types of RNA interference triggers
Olejniczak, M., Urbanek-Trzeciak, M. O., Jaworska, E., Witucki, Ł., Szcześniak, M. W., Makałowska, I., & Krzyżosiak, W. J. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.11.005 · Cited by 23
Evangelista, C. C. S., Guidelli, G. V., Borges, G. D. O., Araujo, T. F., de Souza, T. A. J., Neves, U. P. D. C., Tunnacliffe, A., & Pereira, T. C. (2017) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2017-0030 · Cited by 19
“tions of dicer substrates (10 M) is probably due to: (i) interference in endogenous pathways, such as microRNA biosynthesis (Grimm et al., 2006), (ii) off-targeting, i.”
BackgroundEffective small interfering RNA delivery in vitro via a new stearylated cationic peptide
Chen, P., Chen, B., Ran, P., & Askhatova, D. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s79306 · Cited by 19
“14 Due to the fundamental drawbacks of viral vectors, such as toxicity and immunogenicity, non-viral vectors have served as an alternative because of their advantage in inducing relatively low toxicity and nearly no immune response.”
RNA Interference with Special Reference to Combating Viruses of Crustacea
Fauce, K. A. L., & Owens, L. (2012) · Indian Journal of Virology · doi:10.1007/s13337-012-0084-1 · Cited by 22
“They are incorporated into the RNAi pathway at a later stage and are therefore less likely to interfere with gene regulation by endogenous miRNA [52, 74].”
BackgroundMa, J., Zeng, L., Fan, Y., Zhou, Y. K., Jiang, N., & Chen, Q. (2014) · Virus Research · doi:10.1016/j.virusres.2014.05.009 · Cited by 19
Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies
Kassim, S. H., Wilson, J. M., & Rader, D. J. (2010) · Clinical Lipidology · doi:10.2217/clp.10.73 · Cited by 20
Overview of Gene Silencing by RNA Interference
Kim, D. H., & Rossi, J. J. (2009) · Current Protocols in Nucleic Acid Chemistry · doi:10.1002/0471142700.nc1601s36 · Cited by 22
Metadata
- Authors
- Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Universitätsklinikum Aachen (DE)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 537-541
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1971643509
- Cited by
- 1,677
- References
- 31
- Citations by year
- 2026: 27 · 2025: 32 · 2024: 49 · 2023: 35 · 2022: 57 · 2021: 36 · 2020: 45 · 2019: 54 · 2018: 54 · 2017: 60 · 2016: 75 · 2015: 94 · 2014: 92 · 2013: 121 · 2012: 121
- FWCI
- 57.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- RNA interference, shRNA, microRNA, XPO5, hepatotoxicity, liver injury, AAV8 vector, siRNA delivery, karyopherins, post-transcriptional gene silencing, mice, gene silencing therapy, dose-dependent toxicity
- MeSH terms
- Animals, Hepatitis B virus, Humans, Liver, Liver Regeneration, Mice, Transgenic, Nucleic Acid Conformation, RNA, Survival Analysis, Karyopherins, RNA Interference, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.